FDA grants fast-track status to cancer drug

BOTHELL, Wash. The Food and Drug Administration has given fast-track status to OncoGenex’s cancer treatment OGX-011, OncoGenex announced Friday.

The compound, whose chemical name is custirsen sodium, is undergoing phase II clinical trials for treating various cancers.

The FDA gives fast-track status to drugs in development that could help patients with serious and life-threatening conditions.